Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
Open Access
- 5 January 2006
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 1-6
Abstract
Background: Although numerous chemotherapeutic agents have been tested, the role of systemic chemotherapy for hepatocellular carcinoma (HCC) has not been clarified. New therapeutic strategies are thus needed to improve outcomes, and we designed this study with new effective drug combination. Methods: Twenty-nine patients with histologically-confirmed, metastatic HCC received a combination chemotherapy with doxorubicin 60 mg/m2 and cisplatin 60 mg/m2 on day 1, plus capecitabine 2000 mg/m2/day as an intermittent regimen of 2 weeks of treatment followed by a 1-week rest. Results: The median age was 49 years (range, 32–64) and 19 patients were hepatitis B virus seropositive. Child-Pugh class was A in all patients and 4 had Zubrod performance status of 2. The objective response rate was 24% (95% CI 9–40) with 6 stable diseases. The chemotherapy was generally well tolerated despite one treatment-related death. Conclusion: Combination chemotherapy with doxorubicin, cisplatin and capecitabine produced modest antitumor activity with tolerable adverse effects in patients with metastatic HCC.Keywords
This publication has 30 references indexed in Scilit:
- A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2005
- Systemic therapy for advanced hepatocellular carcinoma: a reviewEuropean Journal of Cancer, 2004
- Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinomaCancer, 2004
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood, 2003
- First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorinAnnals of Oncology, 2002
- Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorinEuropean Journal of Cancer, 2002
- Review article: overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta‐analysis?Alimentary Pharmacology & Therapeutics, 1998
- Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumoursEuropean Journal of Cancer, 1995
- MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosisJournal of Hepatology, 1993
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989